Research groups
Colleges
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Recent publications
-
Dissociation between liver fat content and fasting metabolic markers of selective hepatic insulin resistance in humans
Journal article
Westcott F. et al, (2024), European Journal of Endocrinology (EJE)
-
Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
Preprint
Hodson D. et al, (2024)
-
Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD.
Journal article
Colosimo S. et al, (2024), Diabetes Res Clin Pract
-
Are we putting patients on steroid treatment at risk under anaesthesia?
Journal article
Tomlinson JW., (2024), Anaesthesia
-
Development of diagnostic algorithm for Cushing's syndrome: a tertiary centre experience.
Journal article
Efthymiadis A. et al, (2024), J Endocrinol Invest